YorkBridge Wealth Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

YorkBridge Wealth Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-400	Closed	-$5K	–	702
2019 Q2	$5K	Hold	400	–	–	﹤0.01%	662
2019 Q1	$2K	Hold	400	–	–	﹤0.01%	715
2018 Q4	$1K	Hold	400	–	–	﹤0.01%	730
2018 Q3	$3K	Hold	400	–	–	﹤0.01%	697
2018 Q2	$4K	Hold	400	–	–	﹤0.01%	716
2018 Q1	$4K	Hold	400	–	–	﹤0.01%	707
2017 Q4	$4K	Hold	400	–	–	﹤0.01%	740
2017 Q3	$3K	Buy	+400	New	+$4.23K	﹤0.01%	759

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

YorkBridge Wealth Partners's ZYNE Position: Q3 2019 in Review

YorkBridge Wealth Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2019, closing a stake of 400 shares — an estimated $5K sold.

YorkBridge Wealth Partners first reported a position in ZYNE in Q3 2017 and held it in 8 quarters. The position peaked at $5K in Q2 2019. 84 funds tracked by Wall St. Rank hold ZYNE as of Q3 2019.

YorkBridge Wealth Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
YorkBridge Wealth Partners sold 400 Zynerba Pharmaceuticals, Inc shares in Q3 2019, an estimated $5K.
YorkBridge Wealth Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 8 quarters.
YorkBridge Wealth Partners's Zynerba Pharmaceuticals, Inc position peaked at $5K in Q2 2019.
84 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2019.

Based on YorkBridge Wealth Partners's 13F filing for Q3 2019, filed 21 Oct 2019.